International Isotopes, Inc. engages in the manufacture of nuclear medicine calibration and reference standards cobalt tele therapy sources, as well as radioisotopes and radiochemical for medical research and clinical devices. The company is headquartered in Idaho Falls, Idaho and currently employs 41 full-time employees. The firm's segments include Theranostics Products, Cobalt Products, Nuclear Medicine Standards, Medical Device Products and Fluorine Products. Theranostics Products segment includes production and distribution of its generic sodium iodide I-131 drug product for the treatment of hyperthyroidism and carcinoma of the thyroid. Cobalt Products segment includes the production of bulk cobalt (cobalt-60), fabrication of cobalt capsules for radiation therapy and various industrial applications. Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging. Fluorine Products segment is involved in the production of small-scale qualification samples of high-purity fluoride gas for various industrial applications. The company is working to launch the RadVent brand of medical devices.
INIS stock price ended at $0.07 on 星期四, after dropping 30.00%
On the latest trading day Feb 12, 2026, the stock price of INIS fell by 30.00%, dropping from $0.09 to $0.07. During the session, the stock saw a volatility of 28.57%, with prices oscillating between a daily low of $0.07 and a high of $0.09. On the latest trading day, the trading volume for INIS rose by 1.0K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 41.5K shares were traded, with a market value of approximately $36.9M.